Vaxart, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VXRT | GNLX | IVVD | INO | EVAX | VALN | |
|---|---|---|---|---|---|---|
| Market cap | 97.48M | 88.68M | 186.76M | 167.50M | 26.79M | 533.86M |
| P/E (TTM) | 2.4 | — | — | — | — | — |
| Forward P/E | -0.4 | -2.6 | -1.2 | -3.9 | -198.0 | 4.7 |
| Price/book | 1.2 | 5.4 | 1.0 | 30.6 | 2.6 | 5.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +21.21% | −63.02% | −58.83% | −27.51% | −52.56% | −38.78% |
| Today | 0.00% | +2.08% | +8.96% | −2.41% | +0.34% | +2.18% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VXRT news ›Vaxart Doses 10,000 in Phase 2b COVID-19 Trial
Vaxart dosed the first patient in the 10,000-participant phase of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This trial will compare the efficacy, safety, and immunogenicity of Vaxart's oral vaccine against an…
Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experienceSOUTH... Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors…
More from 1 other outlet
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and c... Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a…
Vaxart granted European patent covering oral norovirus vaccine through 2036
Vaxart (VXRT) announced that the European Patent Office formally published the grant of European Patent No. 3791859 effective August 26. This pa... Vaxart granted European patent covering oral norovirus vaccine through 2036 Vaxart (VXRT)…
Vaxart, Inc. Initial Statement of Beneficial Ownership
Vaxart, Inc. (VXRT) is a clinical-stage biotech developing oral pill vaccines for coronavirus, norovirus, influenza and HPV using a proprietary recombinant platform. - [Form 3] Vaxart, Inc. Initial Statement of Beneficial Ownership…
Vaxart director Bono receives stock and option awards
Netflix Reports Q3 2026 Earnings: Revenue Rises 12% to $12.87 Billion, Operating Margin 34.6% Supermicro Provides First Quarter of Fiscal Year 2027 Preliminary Business Update INOVIO Announces Favorable Judgment in Litigation with VGXI,…
Vaxart (OTCMKTS:VXRT) versus Contineum Therapeutics (NASDAQ:CTNM) Head to Head Review
Posted by Danessa Lincoln on Oct 13th, 2026 Vaxart (OTCMKTS:VXRT – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com3
- stocktitan.net3
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.